

Moving from analytical to diagnostic quality

A study on acquired inhibitors



ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

Disclosures



• Unconditional grant from NOVO Nordisk




ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis











ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

ISO STANDARD 15189





5.6.4 The laboratory shall participate in interlaboratory comparisons such as those organized by external quality assessment schemes. Laboratory management shall monitor the results of external quality assessment and participate in the implementation of corrective actions when control criteria are not furfilled.

External quality assessment programmes should, as far as possible, provide clinically relevant challenges that mimic patient samples and have the effect of checking the entire examination process, including pre- and post-examination procedures.



ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis





with a focus on Thrombosis and Haemostasis

Moving from analytical t diagnostic quality




CASE-BASED EQA

Scope of the project:

Correct diagnosis based on both clinical information and laboratory data

- Interpretation of clinical information
- Evaluation of test request
- Test performance
- Interpretation of laboratory data








ECAT FOUNDATION


External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis





ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis






- physical examination
- potential differential diagnosis



ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis



CASE DESCRIPTION



A general practitioner refers the following patient to you:

An apparently healthy Caucasian man of 67 years old Increased bruising since a few days. No trauma. Question: Any coagulation disorder?

Hematological parameters: normal Prothrombin Time: normal

First examination: At the left-hand side and on the back several purpura and ecchymoses. These came spontaneously approx. 5 days ago. The bruising increases. The largest spot is now 15 cm. These symptoms were not seen before.



ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis



Differential diagnosis

Categories:

- Trauma
- Primary Hemostasis
- Secundary Hemostasis
- Other reasons




ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

Additional patient information?



Drug use Stomach ache Nausia Joint problems **Blood in stools** Tired Weight loss **Fever Disturbed visus Disturbed hearing** Loss of strength Loss of feeling **Breathing complaints Palpitation Micturition**






ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis



Primary hemostasis defects (round 1)






ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis



Secondary hemostasis defects (round 1)





ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

Other reasons (round 1)



Vascular e.c.i.

Vitamin C deficiency

Henoch-Schönlein purpura

Amyloïdosis

Ehlers-Danlos syndrome


Osteogenesis imperfecta

Marfan syndrome

Hereditary hemorrhagic telangiectasia

DIC

sepsis





ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

Thrombocytopenia e.c.i.												
Drug-induced thrombocytopenia												ſ
Leukemia												
Aplastic anemia												
Myelodysplasia												
Splenomegaly												Γ
ITP												
ΤΤΡ												
HUS												
Acquired VWD							Π					
Thrombocytopathy e.c.i.												
Drug-induced thrombocytopathy												
Uremia												
VWD												Γ
												L
Secondary hemostasis e.c.i.												
Vitamin K deficiency												L
Liver disease												
Lupus												
Congenital clotting factor def.												
Inhibitor against clotting factor												L
Use of anticoagulants												
Vascular e.c.i.												
Vitamin C deficiency												
Henoch-Schönlein purpura												
Amyloïdosis												
Ehlers-Danlos syndrome												
Osteogenesis imperfecta												
Marfan syndrome												
Hereditary hemorrhagic telangiectasia												
DIC												
sepsis												



unlikely

possible

very likely


likely

certain



ECAT FOUNDATION

External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis





ECAT FOUNDATION

External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

Thrombocytopenia e.c.i.													Г				
Drug-induced thrombocytopenia																	
Leukemia							Π	Π		Π	T		T	T	П	T	
Aplastic anemia																	
/iyelodysplasia											T		Т	Г		T	
Splenomegaly													T	I			
TP														T			
ПР																	
IUS																	
Acquired VWD		Т											Г				
Thrombocytopathy e.c.i.																	
Drug-induced thrombocytopathy																	1
Jremia																	
WD																	
													I				
Secondary hemostasis e.c.i.																	
/itamin K deficiency																	
liver disease																	
Lupus																	
Congenital clotting factor def.																	
nhibitor against clotting factor																	
Jse of anticoagulants																	
/ascular e.c.i.																	
/itamin C deficiency																	
Henoch-Schönlein purpura																	
Amyloïdosis																	
Ehlers-Danlos syndrome																	
Osteogenesis imperfecta																	
Marfan syndrome																	
Hereditary hemorrhagic telangiectasia																	
DIC												1 1					



unlikely

possible

very likely

likely

certain




ECAT FOUNDATION

External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

Laboratory results (round 1)







ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis



Ordered laboratory tests


	Ordered (1st)
	Ordered (2nd)
Ditternfett Eccel	
(TRacellogy Citizer	
[Ocerdatories	
Luper Aubrecent at	



ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

Laboratory results (round 2)







ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis



Main laboratory results

Parameter	Mean test result	Range
APTT ratio	2.52	2.09 – 3.25
APTT – mix (0 hr.)	1.15	0.83 – 1.35
APTT – mix (1 hr.)	1.35	1.02 – 1.53
APTT – mix (2 hr.)	1.63	1.09 – 2.68
Factor VIII	n.a.	< 1 – 4%
Factor IX	113%	94 – 132%
FVIII Inhibitor	4.4 BU/mL	0.6 – 8.5 BU/mL
Lupus	Negative	
Anticoagulant		
VWF antigen	150%	128 – 172%
VWF activity	120%	100 – 128%



Central Laboratory characteristics



Parameter	Test result	Reference Range
APTT		
APTT ratio		
РТ		
INR		
Fibrinogen		
Thrombin Time (10 IE)		
APTT – mix (0 hr.)		
APTT – mix (1 hr.)		
APTT – mix (2 hr.)		
Factor VIII		
Factor IX		
Factor XI		
FVIII – mix (0 hr.)		
FVIII – mix (0.5 hr.)		
FVIII – mix (1 hr.)		
FVIII Inhibitor		
Lupus Anticoagulant		
VWF antigen		
VWF activity		



ECAT FOUNDATION

External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

Mean likelihood of the differential diagnosis per cycle.

(cycle 1: n=33) (cycle 2: n=32) (cycle 3: n=17)

Aptimat Aptimate Elavianthocyt/operationer to a Note: Aptionalities reservationer to a Note:	1.03 1.01 1.07 1.08 1.08 1.08	tin tin tin tin
Elavitti Locyfoperaio P. C.E	1.11 1.11 1.11/ 1.11/ 1.11/ 1.11	tjæ Tom Lint Tom
Erop miniserf Bromboegiopenna – 1797 Ferdernika – neu- Agionike neu-mini	1.01 1.07 1.08 1.01	tini Lini
Archennia Lon Articettes mentiles Turci	1.87/ 1,595 11,017	List Tim
Ardenthic metatric	T (1) T (1)T	5. j = i
	3003 4.140	
Myellow/yraphanin 1028	CALIFICATION OF	UII
(pph-takanniegpa)(p) b.xtt		L L L
411	211/	6.181
1,16	7,13(1	1.101
	10.00	
Angerit VMD	1,1/	
thronthosylingoility misk		
ting addrect through regulary	3.30	0.101
Avenilia	1.001	
1.04	a.a.c	
Senorthry hermolanic e of. 1.79	3,417	
Minimi Kolisteriney	10.000	07. MG
her dioster.	1.54	
and the second se	3.43	
fangstilal doftry fuctor ett	11.53	0.215
Natsilan agaland shifting basica		A.(2)
Alter of antisonapolitation in the		
Varoadan eug i t <i>as</i> ri	3.77	1.10.
Mianno Catellicionay 3.40	10100	0.101
Bernsch Sithölik II. (illimete		
Amykitti isirs	3,24	CO.
hiera narios syndronie	1,10	
e destruographicies (millary threath)	1.001	1.101
Maritan salepäronne	3.454	1.181
Second the second s	1.107	1111
- <u>- 120</u>	1.013	E. (B.)
1.18 1.18 1.18 1.18 1.18 1.18 1.18 1.18	1,231	1.011






ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

Conclusion after each cycle







ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis



CASE-BASED EQA

Strenghts:

- Focus on the entire diagnostic process.
- Both the physician and the laboratory is included.
- EQA challenge is based on a real clinical scenario

Weaknessess:

- Not all aspects of the total testing process can be included (e.g. sample collection and preparation).
- The physician is guided by an electronic questionnaire and not completely "self-supporting".
- Potential selection of participating physician.



FUTURE DEVELOPMENTS



Based on the experiences so far we will further develop this type of EQA.

- Further optimizing the flow of the survey, e.g. cross-talk between physician and laboratory.
- Other type of disorders.
- Developing electronic interactive tools



ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis





Diagnostic EQA, based on real case scenario's and focussing on the entire diagnostic process, may be an important addition to the current EQA approaches which mainly focus on analytical quality or separate parts of the pre- and post-analytical phase.



Acknowledgement

- Participating hematologists and laboratories
- Piet Meijer (ECAT Foundation)
- Petra ter Hark (ECAT Foundation)
- Marieke Kruip (Erasmus MC)
- Hemostasis Laboratory (Erasmus MC)
- Louise Zandvliet (Novo Nordisk)





ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis





THANK YOU FOR YOUR ATTENTION



ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis